Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -78.92 Billion KRW | 44.48% |
| 2022 | -142.16 Billion KRW | -40.81% |
| 2021 | -100.96 Billion KRW | -675.54% |
| 2020 | -13.01 Billion KRW | 3.16% |
| 2019 | -13.44 Billion KRW | -205.68% |
| 2018 | 12.72 Billion KRW | -35.89% |
| 2017 | 19.84 Billion KRW | 57.74% |
| 2016 | 12.57 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.23 Billion KRW | -288.71% |
| 2024 Q3 | -9.39 Billion KRW | -189.95% |
| 2024 Q1 | -833.32 Million KRW | -158.85% |
| 2023 Q2 | -23.9 Billion KRW | -120.93% |
| 2023 Q3 | -46.02 Billion KRW | -92.51% |
| 2023 Q4 | 1.41 Billion KRW | 103.08% |
| 2023 FY | -78.92 Billion KRW | 44.48% |
| 2023 Q1 | -10.82 Billion KRW | 79.95% |
| 2022 Q4 | -53.98 Billion KRW | -219.86% |
| 2022 Q3 | -16.87 Billion KRW | -133.43% |
| 2022 Q2 | 50.48 Billion KRW | 141.54% |
| 2022 Q1 | -121.52 Billion KRW | -29.65% |
| 2022 FY | -142.16 Billion KRW | -40.81% |
| 2021 Q4 | -93.73 Billion KRW | -1895.64% |
| 2021 Q2 | 11.6 Billion KRW | 190.13% |
| 2021 Q3 | -4.69 Billion KRW | -140.46% |
| 2021 FY | -100.96 Billion KRW | -675.54% |
| 2021 Q1 | -12.88 Billion KRW | 31.92% |
| 2020 FY | -13.01 Billion KRW | 3.16% |
| 2020 Q4 | -18.92 Billion KRW | -2188.94% |
| 2020 Q3 | 905.87 Million KRW | -85.5% |
| 2020 Q1 | -1.24 Billion KRW | 93.92% |
| 2020 Q2 | 6.24 Billion KRW | 600.18% |
| 2019 FY | -13.44 Billion KRW | -205.68% |
| 2019 Q2 | 6.16 Billion KRW | 6.98% |
| 2019 Q3 | -4.81 Billion KRW | -178.15% |
| 2019 Q4 | -20.55 Billion KRW | -326.63% |
| 2019 Q1 | 5.76 Billion KRW | 308.37% |
| 2018 Q4 | -2.76 Billion KRW | -188.22% |
| 2018 Q1 | 6.17 Billion KRW | 44.94% |
| 2018 Q2 | 6.17 Billion KRW | 0.02% |
| 2018 FY | 12.72 Billion KRW | -35.89% |
| 2018 Q3 | 3.13 Billion KRW | -49.25% |
| 2017 Q3 | 7.92 Billion KRW | 49.24% |
| 2017 Q2 | 5.3 Billion KRW | 125.83% |
| 2017 FY | 19.84 Billion KRW | 57.74% |
| 2017 Q4 | 4.26 Billion KRW | -46.22% |
| 2017 Q1 | 2.35 Billion KRW | -73.09% |
| 2016 Q4 | 8.73 Billion KRW | 127.18% |
| 2016 FY | 12.57 Billion KRW | 0.0% |
| 2016 Q3 | 3.84 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -999.141% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 236.108% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | -32.459% |
| HANDOK Inc. | -28.79 Billion KRW | -174.081% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -837.926% |
| Yuhan Corporation | 93.5 Billion KRW | 184.407% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 809.629% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -218.105% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 153.975% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 2349.559% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -3049.049% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -3705.769% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -1644.332% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 453.419% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -999.141% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -276.909% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 2302.623% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 33.264% |
| JW Holdings Corporation | 19.02 Billion KRW | 514.838% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 137.139% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 313.283% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -37.685% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 1389.306% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 4844.595% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 1677.068% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -999.141% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 313.518% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 170.786% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 313.283% |
| Yuhan Corporation | 93.5 Billion KRW | 184.407% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -385.72% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -1936.571% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 1389.84% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 313.283% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 517.482% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 263.542% |
| CKD Bio Corp. | -24.19 Billion KRW | -226.25% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 430.01% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 387.657% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 365.088% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -37.685% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 267.906% |
| Boryung Corporation | 40.2 Billion KRW | 296.325% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | -151.928% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -3049.049% |
| JW Lifescience Corporation | 28.14 Billion KRW | 380.445% |